

iBio, Inc Therapeutic and Overview Pipeline Review H2

iBio, Inc Treatment Pipeline Review H2 2016

PUNE, INDIA, November 11, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by [iBio, Inc.](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649765-ibio-inc-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
- The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses iBio, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features iBio, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate iBio, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding iBio, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

iBio, Inc. Snapshot 6

iBio, Inc. Overview 6

Key Information 6

Key Facts 6

iBio, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

iBio, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

iBio, Inc. - Pipeline Products Glance 13

iBio, Inc. - Clinical Stage Pipeline Products 13

Phase I Products/Combination Treatment Modalities 13

iBio, Inc. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

iBio, Inc. - Drug Profiles 16

anthrax vaccine 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

HAI-05 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

influenza [strain A/H1N1] vaccine 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

malaria vaccine 20

Product Description 20

Mechanism of Action 20
R&D Progress 20
NaAPR1M-74 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
anthrax + plague vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
human papillomavirus [Serotype 16] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IBIOCFB-03 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody for Anthrax 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit Neuraminidase for Influenza 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
palivizumab biosimilar 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
yellow fever vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
influenza [strain A/H7N9] vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Protein for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
trypanosomiasis vaccine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34

[2016](#)

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.